Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

CILOSTAZOL

×

Overview

What is CILOSTAZOL?

DESCRIPTION

H

H

Cilostazol occurs as white to off-white crystals or as a crystalline powder that is slightly soluble in methanol and ethanol, and is practically insoluble in water, 0.1 N HCl, and 0.1 N NaOH.

Cilostazol tablets for oral administration are available as 50 mg or 100 mg round, white debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: carboxymethylcellulose calcium, corn starch, hypromellose, magnesium stearate and microcrystalline cellulose.



What does CILOSTAZOL look like?



What are the available doses of CILOSTAZOL?

Sorry No records found.

What should I talk to my health care provider before I take CILOSTAZOL?

Sorry No records found

How should I use CILOSTAZOL?

Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.

DOSAGE AND ADMINISTRATION

Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.


What interacts with CILOSTAZOL?

Sorry No Records found


What are the warnings of CILOSTAZOL?

Sorry No Records found


What are the precautions of CILOSTAZOL?

Sorry No Records found


What are the side effects of CILOSTAZOL?

Sorry No records found


What should I look out for while using CILOSTAZOL?

Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. Cilostazol tablets are contraindicated in patients with congestive heart failure of any severity.

Cilostazol tablets are contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. Cilostazol tablets inhibit platelet aggregation in a reversible manner.

Cilostazol tablets are contraindicated in patients with known or suspected hypersensitivity to any of its components.

CONTRAINDICATION


What might happen if I take too much CILOSTAZOL?

OVERDOSAGE

50


How should I store and handle CILOSTAZOL?

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].HOW SUPPLIEDThey are supplied as follows:NDC 64720-158-06   in bottles of 60'sNDC 64720-158-10   in bottles of 100'sNDC 64720-158-50   in bottles of 500'sNDC 64720-158-11   in bottles of 1000'sCilostazol tablets 100mg are white,round compressed tablets debossed "cor" over "159" on one side and other side is plain.They are supplied as follows:NDC 64720-159-06   in bottles of 60'sNDC 64720-159-10   in bottles of 100'sNDC 64720-159-50   in bottles of 500'sNDC 64720-159-11   in bottles of 1000'sHOW SUPPLIEDThey are supplied as follows:NDC 64720-158-06   in bottles of 60'sNDC 64720-158-10   in bottles of 100'sNDC 64720-158-50   in bottles of 500'sNDC 64720-158-11   in bottles of 1000'sCilostazol tablets 100mg are white,round compressed tablets debossed "cor" over "159" on one side and other side is plain.They are supplied as follows:NDC 64720-159-06   in bottles of 60'sNDC 64720-159-10   in bottles of 100'sNDC 64720-159-50   in bottles of 500'sNDC 64720-159-11   in bottles of 1000'sHOW SUPPLIEDThey are supplied as follows:NDC 64720-158-06   in bottles of 60'sNDC 64720-158-10   in bottles of 100'sNDC 64720-158-50   in bottles of 500'sNDC 64720-158-11   in bottles of 1000'sCilostazol tablets 100mg are white,round compressed tablets debossed "cor" over "159" on one side and other side is plain.They are supplied as follows:NDC 64720-159-06   in bottles of 60'sNDC 64720-159-10   in bottles of 100'sNDC 64720-159-50   in bottles of 500'sNDC 64720-159-11   in bottles of 1000'sHOW SUPPLIEDThey are supplied as follows:NDC 64720-158-06   in bottles of 60'sNDC 64720-158-10   in bottles of 100'sNDC 64720-158-50   in bottles of 500'sNDC 64720-158-11   in bottles of 1000'sCilostazol tablets 100mg are white,round compressed tablets debossed "cor" over "159" on one side and other side is plain.They are supplied as follows:NDC 64720-159-06   in bottles of 60'sNDC 64720-159-10   in bottles of 100'sNDC 64720-159-50   in bottles of 500'sNDC 64720-159-11   in bottles of 1000'sHOW SUPPLIEDThey are supplied as follows:NDC 64720-158-06   in bottles of 60'sNDC 64720-158-10   in bottles of 100'sNDC 64720-158-50   in bottles of 500'sNDC 64720-158-11   in bottles of 1000'sCilostazol tablets 100mg are white,round compressed tablets debossed "cor" over "159" on one side and other side is plain.They are supplied as follows:NDC 64720-159-06   in bottles of 60'sNDC 64720-159-10   in bottles of 100'sNDC 64720-159-50   in bottles of 500'sNDC 64720-159-11   in bottles of 1000'sHOW SUPPLIEDThey are supplied as follows:NDC 64720-158-06   in bottles of 60'sNDC 64720-158-10   in bottles of 100'sNDC 64720-158-50   in bottles of 500'sNDC 64720-158-11   in bottles of 1000'sCilostazol tablets 100mg are white,round compressed tablets debossed "cor" over "159" on one side and other side is plain.They are supplied as follows:NDC 64720-159-06   in bottles of 60'sNDC 64720-159-10   in bottles of 100'sNDC 64720-159-50   in bottles of 500'sNDC 64720-159-11   in bottles of 1000's


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. Cilostazol tablets are contraindicated in patients with congestive heart failure of any severity.

Cilostazol tablets are contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. Cilostazol tablets inhibit platelet aggregation in a reversible manner.

Cilostazol tablets are contraindicated in patients with known or suspected hypersensitivity to any of its components.

CONTRAINDICATION

Alcohol, ethyl: Hepatotoxicity has occurred in chronic alcoholics following various dose levels (moderate to excessive) of acetaminophen.

Anticholinergics: The onset of acetaminophen effect may be delayed or decreased slightly, but the ultimate pharmacological effect is not significantly affected by anticholinergics.

Oral Contraceptives: Increase in glucuronidation resulting in increased plasma clearance and a decreased half-life of acetaminophen.

Charcoal (activated): Reduces acetaminophen absorption when administered as soon as possible after overdose.

Beta Blockers (Propanolol): Propanolol appears to inhibit the enzyme systems responsible for the glucuronidation and oxidation of acetaminophen Therefore, the pharmacologic effects of acetaminophen may be increased.

Loop diuretics: The effects of the loop diuretic may be decreased because acetaminophen may decrease renal prostaglandin excretion and decrease plasma renin activity.

Lamotrigine: Serum lamotrigine concentrations may be reduced, producing a decrease in therapeutic effects.

Probenecid: Probenecid may increase the therapeutic effectiveness of acetaminophen slightly.

Zidovudine: The pharmacologic effects of zidovudine may be decreased because of enhanced non-hepatic or renal clearance of zidovudine.

Hematologic adverse reactions:

ADVERSE REACTIONS

The only adverse event resulting in discontinuation of therapy in ≥ 3% of patients treated with cilostazol 50 or 100 mg b.i.d. was headache, which occurred with an incidence of 1.3%, 3.5%, and 0.3% in patients treated with cilostazol 50 mg b.i.d., 100 mg b.i.d. or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo.

The most commonly reported adverse events, occurring in ≥ 2% of patients treated with cilostazol 50 or 100 mg b.i.d., are shown in the table below.

Other events seen with an incidence of ≥ 2%, but occurring in the placebo group at least as frequently as in the 100 mg b.i.d. group were: asthenia, hypertension, vomiting, leg cramps, hyperesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis.

Less frequent adverse events (< 2%) that were experienced by patients exposed to cilostazol 50 mg b.i.d. or 100 mg b.i.d. in the eight controlled clinical trials and that occurred at a frequency in the 100 mg b.i.d. group greater than in the placebo group, regardless of suspected drug relationship, are listed below.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).